Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Real Life Study of Biologicals in Patients With Severe CRSwNP

Real Life Study Assessing Long Term Outcomes and Predictive Factors of Response to Biologicals in Patients With Severe CRSwNP and/or Severe Allergic and/or Eosinophilic Asthma

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study is a pragmatic, real-life, observational study recruiting adult patients with chronic rhinosinusitis with nasal polyposis who are eligible to start biologicals as standard treatment. The aim of this study is to observe the long-term outcomes of biologicals in CRSwNP patients with or without comorbid asthma in 'real life'. Moreover, the investigators will gain insight into the mechanisms of biologicals in the local and systemic immunity of these patients and investigate novel local and systemic biomarkers and predictors of response.

Who May Be Eligible (Plain English)

Who May Qualify: Patients must meet the following criteria to be eligible for the enrolment in the study: - Signed willing to sign a consent form form (ICF), - Age between 18 and 80 years at time of signing ICF, - Able to comply with the study protocol, in the investigator's judgment, - In group one: patients with severe allergic and/or eosinophilic asthma, defined by being currently treated with a biological (SoC) OR starting treatment with a biological (SoC). - In group two: patients with CRSwNP with or without asthma, defined by starting treatment with a biological (SoC) and fulfill the criteria for reimbursement of a biological therapy Who Should NOT Join This Trial: Patients who do not meet the reimbursement criteria of a biological therapy cannot participate in the study. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: Patients must meet the following criteria to be eligible for the enrolment in the study: * Signed informed consent form (ICF), * Age between 18 and 80 years at time of signing ICF, * Able to comply with the study protocol, in the investigator's judgment, * In group one: patients with severe allergic and/or eosinophilic asthma, defined by being currently treated with a biological (SoC) OR starting treatment with a biological (SoC). * In group two: patients with CRSwNP with or without asthma, defined by starting treatment with a biological (SoC) and fulfill the criteria for reimbursement of a biological therapy Exclusion Criteria: Patients who do not meet the reimbursement criteria of a biological therapy cannot participate in the study.

Treatments Being Tested

BIOLOGICAL

Mepolizumab

Monoclonal antibodies

Locations (1)

Ghent University Hospital
Ghent, Belgium